Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02661815 · ClinicalTrials.gov registry record · Phase 1
A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT02661815 is a Phase 1 study that was terminated before completion, run by Dana-Farber Cancer Institute. The registered enrollment target is 6 participants.
The verdict
NCT02661815, a Phase 1 study, was terminated before completion, sponsored by Dana-Farber Cancer Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
Participants with Ovarian, Fallopian Tube, or Peritoneal Cancer that has recurred within 12 months of prior treatment that includes Platinum Chemotherapy are invited to take part in this study. This research study is studying a combination of a new chemotherapy drug called Ricolinostat together with the chemotherapy Paclitaxel and a drug called Bevacizumab as a possible treatment for this diagnosis.
Interventions
- DRUG Bevacizumab
- DRUG Paclitaxel
- DRUG Ricolinostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2016-06-15 |
| Est. Completion | 2017-07-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02661815
The ClinicalTrials.gov registry entry for NCT02661815 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bevacizumab is the first listed.
NCT02661815 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02661815 about?
NCT02661815 is a clinical study titled "A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer". Participants with Ovarian, Fallopian Tube, or Peritoneal Cancer that has recurred within 12 months of prior treatment that includes Platinum Chemotherapy are invited to take part in this study. This research study is studying a combination of a new chemotherapy drug called Ricolinostat together with...
What is the current status of trial NCT02661815?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2016-06-15. Estimated completion is 2017-07-28.
What interventions are being tested in trial NCT02661815?
The interventions under investigation include: Bevacizumab (DRUG), Paclitaxel (DRUG), Ricolinostat (DRUG).
Who is sponsoring clinical trial NCT02661815?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.